Who We Are

Steve Bradshaw

BSc (Hons.), MB BChir, MRCOphth

Managing Director

Steve Bradshaw is Managing Director of Valid Insight. He has two decades’ experience in market access consulting and healthcare. He has developed price and access strategies and value communication tools for many well-known products on the market, and has supported numerous companies on many aspects of market access, pricing, tendering, contracting, value communication and operational excellence.

Steve’s career includes being Editor at Nature Clinical Reviews, Ophthalmic Surgeon UK National Health Service, and various positions to senior executive level in market access consulting firms including United BioSource Corporation, Evidera and Market Access Solutions LLC, prior to launching Valid Insight. His education includes a first-class BSc in Biochemistry, degrees in Medicine and Surgery from Gonville and Caius College, Cambridge, and a postgraduate diploma in Ophthalmology.

Steve writes and speaks regularly on the challenges facing the global healthcare environment; he presents widely at conferences and expert panels, and has authored over 30 publications. His research interests span multiple therapy areas across drugs, devices and biotechnologies, including innovative medicines for rare diseases. He is a peer reviewer for several medical journals, Editorial Board Member for the journal Medicine Access @ Point of Care, Advisory Board Member at Pharma-IQ and the Global Pneumonia Prevention Coalition, and has been quoted in publications such as BioPharm Insight, Hospital Pharmacy Europe, and Reuters.

Raf De Wilde

PhD

Senior Executive Advisor

Raf De Wilde is Senior Executive Advisor at Valid Insight. He is a global expert in life science market access, having over 37 years’ experience in the pharmaceutical industry and over 27 years in global market access.

Raf became the head of International Marketing Services within Janssen Pharmaceutica (a Johnson & Johnson (J&J) company) in 1991, introducing Health Economics at J&J that year. Raf was Chairman of EPhMRA Primary Research and Methods Committee (1993-1995). He became VP of EPhMRA in 1994 and 1997 and President in 1995 and 1998.

In 1997, he joined Peter Lauper’s team that pioneered the ‘biosimilars’ concept and the first patient access schemes. Raf led a specialist oncology, real-world evidence and virology group between 2002 and 2004, where he created a centre of excellence for oncology pricing and specialised in biologics while leading the HEOR function at CENTOCOR. Raf was VP of Market Access at J&J leading teams working on oncology, cardiovascular and biotech products from 2004 to 2010.

Raf joined United Biosource Corporation (UBC) as Associate VP in early 2011 and stayed with Evidera until 2015, prior to joining Valid Insight in 2016. In his consulting career he has led over 100 global market access projects, including value strategies, price finding research, patient access schemes, negotiation tactics, tendering and contracting, WHO classification and naming strategies. He has moderated over 120 training workshops in Asia, Asia-Pacific, Europe, North America and Middle-East, and led the life sciences pricing training of the European Pricing Platform from 2011 to 2014.

Raf continues to teach the sessions on PROs and evidence-based medicine at the Master of Science in Pharmaceutical Medicine course of the University of Duisburg-Essen in Germany.

Crispin Jenkinson
BA, MA, MSc, DPhil

Senior Advisor

Crispin Jenkinson is Senior Advisor at Valid Insight. He is Professor of Health Services Research, Director of the Health Services Research Unit at the Nuffield Department of Population Health, and a Senior Research Fellow of Harris Manchester College at the University of Oxford. He graduated from Bedford College (University of London) before coming to Oxford where he gained an MSc in Psychology and then undertook research on the psychological impact of long-term illness for a DPhil. His main research interests include patient reported outcomes (PROs) and health status measurement, the evaluation of patient experiences of medical care, and methodology. He has extensive experience of developing and validating outcome measures and, in collaboration with others, has conducted randomised controlled trials in which such instruments have been primary end-points. This work has led to the development of several internationally recognized PRO measures including the Parkinson’s Disease Questionnaire (PDQ), Amyotrophic Lateral Sclerosis Questionnaire (ALSAQ), and the Endometriosis Health Profile (EHP). He has written and edited many books as well as having authored over 210 peer reviewed publications.

Crispin helps our clients develop fit-for-purpose PRO and other health status instruments.

Carole Alison Chrvala
MA, PhD

Senior Advisor

Carole Chrvala is Senior Advisor at Valid Insight. She has over 25 years’ experience as an epidemiologist and HEOR researcher. Her work spans collaborations with government health agencies, payers, academic institutions, pharmaceutical and medical device companies, medical education and communication organisations, and healthcare professional societies located in the US, UK, EU, and Israel. Carole is highly experienced in epidemiologic consulting, biostatistical support, strategic competitive analysis, medical intelligence, medical writing and publication planning services in diverse therapeutic areas including oncology, cardiovascular disease, diabetes mellitus, infectious diseases, musculoskeletal disorders, neurologic disorders, pain, psychiatric disorders, rare diseases, respiratory disorders, rheumatologic disorders, and women’s health.

Carole has developed and validated risk prediction models for various chronic and infectious diseases, analysed health care resource utilisation and economic burden, determined projections for the global epidemiologic burden of diverse health conditions, developed prospective and retrospective research studies to examine the impact of clinical interventions and developed statistical analysis plans for retrospective and prospective case-control studies and randomised clinical trials.

Carole was director of Cancer Prevention and Control for the Colorado Department of Public Health and Environment (CDPHE), before setting up her own independent company. She joined the US Food and Drug Administration as a Senior Scientist and later joined the National Academies of Science as a Senior Program Officer. She has written and presented on epidemiology, health economics and outcomes research, and diverse health topics to more than 75 professional audiences and organisations.

James Wright
Dip HE, MSc

Director

James Wright is a Director at Valid Insight and has over twenty years’ experience in the healthcare industry and consulting. He joined Valid Insight after 13 years at QuintilesIMS.

James has provided market access support to most of the top 25 pharmaceutical companies and has extensive experience in HTA optimisation, evaluation of strategic pricing and market access implications for new launches, and product/portfolio lifecycle optimisation. James’ experience covers all major therapy areas, including rare and orphan disease, plus extensive work in biologics across established and emerging markets. James also specialises in clinical trial assessment, payer positioning, value and pricing strategy and lifecycle management.

James has an MSc in Health Economics and Pharmacoeconomics from Universitat Pompeu Fabra.

Carolyn Steeds
BSc (Hons), PGCert Health Economics

Associate Director – Value Comms

Carolyn has 30 years’ experience in the healthcare industry, comprising 15 years in pharmaceuticals, 12 years in consultancy and 3 years in diagnostics. Over 20 years of this time has been spent working in HEOR and Market Access where Carolyn gained considerable experience in developing: value dossiers and key value messages, market access strategies, value communication tools, health economic data to support pricing and reimbursement and outcomes research studies.

Carolyn worked for many years in consultancy as an independent consultant in the area of HEOR and value communications, and for several years in market access consultancy. Carolyn has managed numerous projects working with large global pharmaceutical companies to smaller diagnostic manufacturers delivering high quality deliverables across a wide range of therapy areas including; oncology, infectious diseases, neurology, ophthalmology, medical devices (insulin pumps, gastric bands) and in-vitro Diagnostics (biomarker testing for cancer, molecular assays for infection).

Most recently Carolyn was responsible for developing value messages, with supporting clinical and economic evidence, and the appropriate value communication tools to support adoption of new assays for the diagnosis of infectious diseases.

Carolyn has an honours degree in Biology from Strathclyde University and a postgraduate certificate in Health Economics from Aberdeen University.